# | Title | Journal | Year | Citations |
---|
1 | Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011 | Modern Rheumatology | 2012 | 1,294 |
2 | Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011 | Modern Rheumatology | 2012 | 947 |
3 | A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details | Modern Rheumatology | 2012 | 662 |
4 | A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details | Modern Rheumatology | 2012 | 453 |
5 | Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy | Modern Rheumatology | 2009 | 312 |
6 | A new conceptualization for Mikulicz's disease as an IgG4-related plasmacytic disease | Modern Rheumatology | 2006 | 283 |
7 | Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients | Modern Rheumatology | 2016 | 281 |
8 | Revised Japanese criteria for Sjögren’s syndrome (1999): availability and validity | Modern Rheumatology | 2004 | 256 |
9 | Risk of malignancies in IgG4-related disease | Modern Rheumatology | 2012 | 244 |
10 | Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy | Modern Rheumatology | 2009 | 228 |
11 | Control of chondrogenesis by the transcription factor Sox9 | Modern Rheumatology | 2008 | 223 |
12 | The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD | Modern Rheumatology | 2021 | 219 |
13 | A new conceptualization for Mikulicz's disease as an IgG4-related plasmacytic disease | Modern Rheumatology | 2006 | 208 |
14 | Current approach to the diagnosis of IgG4-related disease – Combination of comprehensive diagnostic and organ-specific criteria | Modern Rheumatology | 2017 | 175 |
15 | Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease | Modern Rheumatology | 2013 | 170 |
16 | Risk of malignancies in IgG4-related disease | Modern Rheumatology | 2012 | 162 |
17 | Control of chondrogenesis by the transcription factor Sox9 | Modern Rheumatology | 2008 | 161 |
18 | Quality of life and self-reported disability in patients with knee osteoarthritis | Modern Rheumatology | 2014 | 149 |
19 | IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review | Modern Rheumatology | 2019 | 134 |
20 | Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis | Modern Rheumatology | 2007 | 130 |
21 | Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions | Modern Rheumatology | 2010 | 127 |
22 | Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I) | Modern Rheumatology | 2014 | 124 |
23 | Colchicine versus placebo in Behçet’s disease: randomized, double-blind, controlled crossover trial | Modern Rheumatology | 2009 | 114 |
24 | Value of serum IgG4 in the diagnosis of IgG4-related disease and in differentiation from rheumatic diseases and other diseases | Modern Rheumatology | 2012 | 111 |
25 | Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study | Modern Rheumatology | 2015 | 109 |
26 | Epidemiology of nontraumatic osteonecrosis of the femoral head in Japan | Modern Rheumatology | 2015 | 109 |
27 | A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus | Modern Rheumatology | 2007 | 107 |
28 | Overexpression of microRNA-223 in rheumatoid arthritis synovium controls osteoclast differentiation | Modern Rheumatology | 2013 | 107 |
29 | Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions | Modern Rheumatology | 2010 | 107 |
30 | Prevalence of disease-specific antinuclear antibodies in general population: estimates from annual physical examinations of residents of a small town over a 5-year period | Modern Rheumatology | 2008 | 105 |
31 | Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study | Modern Rheumatology | 2014 | 105 |
32 | Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study | Modern Rheumatology | 2008 | 104 |
33 | Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study | Modern Rheumatology | 2009 | 104 |
34 | Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis | Modern Rheumatology | 2019 | 104 |
35 | Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients | Modern Rheumatology | 2011 | 103 |
36 | Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs | Modern Rheumatology | 2011 | 103 |
37 | Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of 7740 patients | Modern Rheumatology | 2014 | 100 |
38 | Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases | Modern Rheumatology | 2009 | 98 |
39 | A case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab | Modern Rheumatology | 2012 | 97 |
40 | Cartilage destruction by matrix degradation products | Modern Rheumatology | 2006 | 96 |
41 | Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study | Modern Rheumatology | 2009 | 96 |
42 | Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis | Modern Rheumatology | 2019 | 96 |
43 | Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis | Modern Rheumatology | 2011 | 95 |
44 | Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome | Modern Rheumatology | 2011 | 95 |
45 | Epidemiology of the locomotive syndrome: The research on osteoarthritis/osteoporosis against disability study 2005–2015 | Modern Rheumatology | 2017 | 93 |
46 | Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis | Modern Rheumatology | 2007 | 92 |
47 | A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus | Modern Rheumatology | 2007 | 92 |
48 | Everyday clinical practice in IgG4-related dacryoadenitis and/or sialadenitis: Results from the SMART database | Modern Rheumatology | 2015 | 91 |
49 | Autoimmune-associated hemophagocytic syndrome | Modern Rheumatology | 2004 | 90 |
50 | Treatment of retinal vasculitis in Behçet's disease with rituximab | Modern Rheumatology | 2008 | 90 |